Home Newsfeeds BTIG Downgrades IronNet to Sell

BTIG Downgrades IronNet to Sell

BTIG analyst Gray Powell downgrades IronNet (NYSE:IRNT) from Neutral to Sell.

byBenzinga Newsdesk

September 15, 2022

1 minute read

BTIG analyst Gray Powell downgrades IronNet (NYSE:IRNT) from Neutral to Sell.

Investigator Says Apellis’ Lead Product Shows ‘First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth’

By Vandana Singh

October 3, 11:38 AM

Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan for geographic atrophy (GA) secondary…

APLS

Needham Maintains Buy on Nutanix, Raises Price Target to $25

By Benzinga Newsdesk

September 1, 6:39 AM

Needham analyst Mike Cikos maintains Nutanix (NASDAQ:NTNX) with a Buy and raises the price target from $20 to $25.

NTNX

Orgenesis Announces Proposed Underwritten Public Offering; No Size Or Amount Disclosed

By Benzinga Newsdesk

October 30, 5:00 PM

Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it has commenced an underwritten public

ORGS

Target, Holley, Ferroglobe And Other Big Losers From Wednesday

By Lisa Levin

November 17, 3:31 AM

U.S. stocks closed mostly lower on Wednesday, with the Nasdaq Composite dropping around 175 points. Here is the list of some big stocks recording losses in the previous session.

AAP

BTIG Downgrades IronNet to Sell

Related Posts

Investigator Says Apellis’ Lead Product Shows ‘First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth’

Needham Maintains Buy on Nutanix, Raises Price Target to $25

Orgenesis Announces Proposed Underwritten Public Offering; No Size Or Amount Disclosed

Target, Holley, Ferroglobe And Other Big Losers From Wednesday